
    
      This is a double-blind, randomized, placebo-controlled multi-center study consisting of 3
      cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated
      sequentially in ascending dose order. Subjects will be randomized to either an active dose of
      CTP-543 or placebo for a 24-week treatment period.
    
  